OncoMatch/Clinical Trials/NCT06275360
Repositioning Immunotherapy in VetArans With Lung Cancer
Is NCT06275360 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Nivolumab for non-small cell lung cancer.
Treatment: Nivolumab — This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) tumor expression greater than or equal to 1% (>=1%)
PD-L1 tumor expression greater than or equal to 1%
Required: EGFR mutation
Tumor with known EGFR, ALK, ROS1, MET or RET mutations/fusions
Required: ALK fusion
Tumor with known EGFR, ALK, ROS1, MET or RET mutations/fusions
Required: ROS1 fusion
Tumor with known EGFR, ALK, ROS1, MET or RET mutations/fusions
Required: MET mutation
Tumor with known EGFR, ALK, ROS1, MET or RET mutations/fusions
Required: RET fusion
Tumor with known EGFR, ALK, ROS1, MET or RET mutations/fusions
Disease stage
Required: Stage III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: thoracic radiotherapy
Prior thoracic radiotherapy
Cannot have received: systemic treatment
prior systemic treatment for stage IIIB/IV NSCLC
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT · West Haven, Connecticut
- VA Central Office, Washington, DC · Washington D.C., District of Columbia
- Richard L. Roudebush VA Medical Center, Indianapolis, IN · Indianapolis, Indiana
- VA Ann Arbor Healthcare System, Ann Arbor, MI · Ann Arbor, Michigan
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE · Omaha, Nebraska
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06275360 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 tumor expression greater than or equal to 1% is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR mutation is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK fusion is a required biomarker for enrollment.
What disease stage is eligible?
Stage III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify